ArticleJournal of virology2010
Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016Pooled it
- Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland.Biomolecules · 2025Article
- A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades.NPJ vaccines · 2020Article
- Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Biomedicines · 2017Review
- Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.Journal of virology · 2015Article
- Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.The Journal of infectious diseases · 2015Article
- A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Journal of virology · 2015Article
- The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Article
- Virus-vectored influenza virus vaccines.Viruses · 2014Review
- Article
- VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.Journal of virology · 2014Article
- Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters.Viruses · 2014Article
- Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.Journal of virology · 2014Article
- Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.Influenza and other respiratory viruses · 2013Article
- Immunobiology of influenza vaccines.Chest · 2013Review
- Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.Future virology · 2013Article
- The synthetic futures of vesicular stomatitis virus.Trends in biotechnology · 2012Article
- Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.Nature biotechnology · 2012Article
- Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.Journal of virology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (J. A. Schwartz et al., Virology 366:166-173, 2007). Here we have generated and characterized VSV-based vaccines that express the A/Hong Kong/156/1997 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Postchallenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.